Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY Trial: Lisaftoclax, Chidamide, and Rituximab in R/R DLBCL
NCT07601607Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lisaftoclax in diffuse large B-cell lymphoma (DLBCL), sponsored by Sun Yat-sen University. Planned start May 2026; status: not yet recruiting.
02
Drugs
lisaftoclax
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07601607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07601607.